In asthma, increased inflammation, as measured by the SII, is independently linked to greater mortality risk (all-cause, CV and respiratory).

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Asthma is a chronic inflammatory disease that affects the lungs. In a child with asthma, the airways are very sensitive, ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

A study reveals that shape-shifting immune cells, intermediate ILC2s, may contribute to severe asthma and resistance to ...

A set of chameleon-like immune cells could be contributing to severe asthma in some patients.Intermediate group 2 i ...

Asthma represents a substantial health burden in childhood globally, with minoritised populations being disproportionately impacted.1 Recent literature has increasingly linked social determinants of ...